VBI Vaccines Announces Results of Annual General Meeting

VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting

BusinesswireJun 26 04:15

VBI Vaccines Shows Promise in Glioblastoma Trial

TipRanksMay 29 20:34

Express News | VBI Vaccines Inc: Expect to Have Additional Tumor Response Data and Initial Survival Data Throughout Remainder of 2024

BreakingsMay 29 20:02

Express News | VBI Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study of VBI-1901 in Recurrent Glioblastoma Patients

BreakingsMay 29 20:00

VBI Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's immunotherapeutic cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients.

VBI VaccinesMay 29 12:00

VBI Vaccines' Promising Glioblastoma Treatment Data

TipRanksMay 22 20:43